临床试验/NL-OMON44611

NL-OMON44611已完成不适用

A Phase I, open-label, drug-drug interaction study between multiple oral doses of GLPG1972 and a single dose of midazolam in healthy male subjects. - DDI study between GLPG1972 and Midazolam in healthy male subjects.

Galapagos NV0 个研究点目标入组 18 人开始时间: 待定最近更新: 2024年2月28日

试验速览

阶段: 不适用
状态: 已完成
发起方: Galapagos NV
入组人数: 18

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 64（—）

入选标准

•healthy male volunteers
•18 - 50 years, inclusive
•BMI 18.0 - 30.0 kg/m2
•weight at least 50 kilograms
•non smokers

排除标准

•Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study. Not allowed is the use of any prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g. St. John*s Wort), from 14 days prior to the first administration of the study compound until the post-study visit.

研究者

发起方

相似试验

Phase 1 Drug-Drug Interaction Study between TAK-272 and Itraconazole, Digoxin and Midazolam

JPRN-jRCT2080222758TAKEDA PHARMACEUTICAL COMPANY LTD.34

A phase 1 study to evaluate drug-drug interactions of Bojungikgitang with Clopidogrel, Atorvastatin, and Fimasartan/Amlodipine in healthy adult volunteers

KCT0007296Kyunghee University-industry Cooperation Foundation42

A Phase 1 Drug-Drug Interaction Study to Assess the Interaction Potential of NB-4746 on CYP1A2 and CYP3A4 Substrates in Healthy Volunteers

ACTRN12624001072505ura Bio18

An open-label, add-on, drug-drug interaction study to assess the effect of FYX-051 on the pharmacokinetics and safety of warfarin in Japanese healthy adult maleHealthy adult male

JPRN-jRCT2080221293SANWA KAGAKU KENKYUSHO CO.,LTD.12

进行中（未招募）

A study in healthy volunteers to discover how the test medicine interacts with other approved medicines1. Non-alcoholic steatohepatitis (NASH)2. Antipsychotic-induced weight gain (AIWG)

ISRCTN10379288Corcept Therapeutics (United States)30